Fluoxetine
Fluoxetine is a selective serotonin reuptake inhibitor prescribed to heal depression or obsessive-compulsive disorder in adults.
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 180 | $0.34 | $62.00 (0%) | 🛒 Add to cart |
| 360 | $0.31
Best per cap | $124.00 $111.00 (10%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $0.67 | $40.00 (0%) | 🛒 Add to cart |
| 90 | $0.60 | $60.00 $54.00 (10%) | 🛒 Add to cart |
| 120 | $0.56 | $80.00 $67.00 (16%) | 🛒 Add to cart |
| 180 | $0.53 | $120.00 $95.00 (21%) | 🛒 Add to cart |
| 270 | $0.51 | $180.00 $137.00 (24%) | 🛒 Add to cart |
| 360 | $0.50
Best per cap | $240.00 $179.00 (25%) | 🛒 Add to cart |
Synonyms
| |||
Similar products
More info:
Abilify: Advanced Antipsychotic for Symptom Control and Stability
Abilify (aripiprazole) is an atypical antipsychotic medication engineered to provide a sophisticated mechanism of action for managing complex psychiatric conditions. It functions as a partial agonist, offering a unique modulatory effect on dopamine and serotonin receptors, which contributes to its efficacy and generally favorable tolerability profile. This medication is a cornerstone in the long-term management of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder, providing patients with a path toward sustained symptom control and improved functional outcomes.
Amitriptyline: Effective Relief for Chronic Pain and Depression
Amitriptyline is a tricyclic antidepressant (TCA) with a well-established profile for managing major depressive disorder and a range of chronic pain conditions. Its dual-action mechanism modulates serotonin and norepinephrine reuptake, offering both mood stabilization and central pain modulation. It is particularly valued in clinical practice for its efficacy in neuropathic pain, migraine prophylaxis, and as a second-line option for depression when SSRIs are ineffective or poorly tolerated. This product card provides a comprehensive, evidence-based overview for healthcare professionals.
Anafranil: Restoring Balance in Severe OCD Treatment
Anafranil (clomipramine hydrochloride) is a tricyclic antidepressant (TCA) with potent serotonin reuptake inhibition properties, specifically approved for the treatment of obsessive-compulsive disorder (OCD). It represents a foundational pharmacological intervention for moderate to severe OCD cases where first-line treatments prove insufficient. Its efficacy is well-documented in clinical literature, offering a robust option for patients struggling with intrusive thoughts and compulsive behaviors. By modulating key neurotransmitter systems, it helps reduce the core symptoms that significantly impair daily functioning and quality of life.
Asendin: Targeted Relief for Endogenous Depression with Dual-Action Efficacy
Asendin (amoxapine) is a tetracyclic antidepressant (TeCA) medication indicated for the relief of symptoms of endogenous depression. It represents a distinct class of agent that combines potent norepinephrine reuptake inhibition with secondary dopamine receptor blockade, offering a unique neurochemical profile for cases where first-line selective serotonin reuptake inhibitors (SSRIs) prove inadequate or intolerable. Its mechanism provides a rapid onset of action for certain symptoms, particularly psychomotor retardation, often within the first week of treatment.
Effexor XR: Sustained Relief for Major Depressive Disorder
Effexor XR (venlafaxine hydrochloride) is an extended-release antidepressant belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is specifically formulated to provide continuous, 24-hour delivery of the active ingredient, maintaining stable plasma concentrations and supporting consistent therapeutic effect. This medication is indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. Its dual mechanism offers a broader neurochemical approach compared to SSRIs, potentially benefiting patients with inadequate response to first-line treatments.
Endep: Restore Restful Sleep and Relieve Chronic Pain
Endep (amitriptyline hydrochloride) is a tricyclic antidepressant (TCA) with established efficacy in managing neuropathic pain and sleep disorders. While originally developed for depression, its potent analgesic and sedative properties have made it a cornerstone in off-label treatment protocols for various chronic conditions. This medication works by increasing the levels of certain neurotransmitters in the brain, namely serotonin and norepinephrine, which modulate pain perception and sleep-wake cycles. Its dual-action profile offers a strategic therapeutic option for patients unresponsive to first-line analgesics or those with comorbid insomnia.
Mellaril: Advanced Neuroleptic Therapy for Schizophrenia Management
Mellaril (thioridazine hydrochloride) is a first-generation phenothiazine antipsychotic medication indicated for the management of manifestations of schizophrenia in patients who have not responded adequately to treatment with other antipsychotic drugs. As a potent dopamine D2 receptor antagonist, it exerts its primary therapeutic effect by blocking postsynaptic mesolimbic dopaminergic receptors in the brain, thereby reducing the positive symptoms of psychosis, including hallucinations, delusions, and thought disorder. Its use requires careful patient selection and vigilant monitoring due to its specific side effect profile, particularly concerning cardiac conduction abnormalities.
Ventodep ER: Advanced Sustained-Release Depression Therapy
Ventodep ER is a next-generation extended-release antidepressant designed for precision neurochemical modulation in the treatment of major depressive disorder (MDD). Its unique pharmacokinetic profile ensures stable plasma concentrations, minimizing peak-trough fluctuations associated with conventional formulations. Clinically validated to enhance therapeutic adherence and reduce discontinuation symptoms, it represents a significant advancement in psychopharmacological management. This formulation is particularly indicated for patients requiring long-term maintenance therapy and those with sensitivity to abrupt neurotransmitter shifts.
Bupropion SR: Effective Relief for Major Depressive Disorder
Bupropion SR (sustained-release) is a widely prescribed antidepressant belonging to the aminoketone class, distinct from SSRIs and SNRIs. It functions primarily as a norepinephrine–dopamine reuptake inhibitor (NDRI), offering a unique mechanism of action for managing major depressive disorder. This formulation provides steady plasma concentrations over 12 hours, supporting consistent therapeutic effect with twice-daily dosing. Clinicians often favor bupropion SR for its favorable side effect profile, particularly the low incidence of sexual dysfunction and weight gain associated with other antidepressants.